Bison Botanics

In July 2026, Bison Botanics concentrated 46.79% of sales in Flower with a year-over-year decline of 23.66% but a month-over-month uptick of 1.30%, while Vapor Pens held 23.89% share with a 26.52% YoY drop and a 0.81% MoM gain. Pre-Roll accounted for 15.00% share yet fell 47.94% YoY and 9.38% MoM, contrasting with Beverage at 9.37% share that contracted 16.33% YoY but expanded 8.39% MoM. Smaller lines were volatile: Concentrates slid 12.27% MoM with no YoY reading, Topical rose 27.74% MoM despite a 9.93% YoY dip, and the long-tail Edible and Tincture & Sublingual shrank 55.05% MoM and 65.96% MoM respectively after steep YoY declines of 91.34% and 77.93%. With average price down 10.06% YoY to $21.99 and Flower ranked 94th in New York, the pattern implies a defensive shift toward price-accessible core segments where modest MoM stabilization can offset deep YoY erosion in satellite categories.

The mix changes imply Bison Botanics is leaning on Flower and Vapor Pens for baseline velocity while de-emphasizing riskier long-tail formats, as seen in Pre-Roll’s 47.94% YoY decline alongside Beverage’s 8.39% MoM growth that helps diversify without relying on high-ticket items. The 27.74% MoM lift in Topical, paired with Concentrates’ 12.27% MoM pullback and the extreme contraction in Edible and Tincture & Sublingual at 55.05% and 65.96% MoM, indicates selective pruning rather than broad expansion. Coupled with a 10.06% YoY price reduction and a 1.30% MoM Flower rise within a 94th-place Flower ranking in New York, the thesis is that Bison Botanics is trading margin for traffic in its two largest categories while testing a narrower set of adjacency bets where month-over-month improvement can translate into share defense despite brand-level sales down 29.18% YoY.